clinical trial · NCT07241234
A Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AG-181 in Subjects With Phenylketonuria
PhenylketonuriaAG-181
brief summary
The primary purpose of this study is to assess the safety and tolerability of AG-181 in subjects with Phenylketonuria (PKU).
started
Apr 17, 2026
primary completion
Jan 17, 2028
completion
Jan 17, 2028
last updated
May 29, 2026
official title
A Phase 1b, Open-label, Multicenter, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of AG-181 in Subjects With Phenylketonuria
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol